Affordable Access

[Results of open post-registration clinical trials of copaxone in patients with multiple sclerosis].

Authors
  • Zavalishin, I A
  • Gusev, E I
  • Iakhno, N N
  • Ronkin, M A
  • Shmidt, T E
  • Demina, T L
  • Kugoev, A I
  • Adarcheva, L S
  • Niiazbekova, A S
  • Zakharova, M N
  • Peresedova, A B
  • Toropina, G G
  • Klishevskaia, L A
  • Maksimenko, I M
  • Krotenkova, M V
  • Konovalov, S N
  • Rebrova, O Iu
  • Zhuchenko, T D
Type
Published Article
Journal
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoĭ promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe obshchestvo nevrologov [i] Vserossiĭskoe obshchestvo psikhiatrov
Publication Date
Jan 01, 2002
Volume
Suppl
Pages
59–64
Identifiers
PMID: 12418394
Source
Medline
License
Unknown

Abstract

Results of the 2-year open postregistration study of Copaxone (glatiramer acetate), conducted in 3 Moscow leading medical centres are given. 32 MS patients with remitting-relapsing MS were investigated in accordance with international requirements (neurological scales, MRI of the brain, multimodal evoked potential). Significant reduction of annual relapse rate for 70.3%, stabilization of neurological status and benign safety profile were demonstrated during Copaxone treatment. Practical recommendations for Copaxone use are given.

Report this publication

Statistics

Seen <100 times